Blue Water Vaccines appoints Timothy Ramdeen to board; Kimberly Murphy resigns

Onconetix, Inc.

Kimberly Murphy resigned from Board, Nominating, Compensation, and Audit Committees effective Jan 13, 2023; no disagreement with company.
Board appointed Tim Ramdeen, founder/managing partner of Dharma Capital Advisors, to replace Murphy.
Ramdeen will chair Nominating Committee and serve on Compensation and Audit Committees.
Ramdeen brings nearly a decade of private equity and hedge fund investing experience, including at Altium Capital and Sixth Borough Capital.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Kimberly Murphy

Director

ONCO · Onconetix, Inc.

Effective: 2023-01-13
Successor: Tim Ramdeen
Filed: January 17, 2023, 6:59 PM ET

Effective as of January 13, 2023, Kimberly Murphy resigned as a member of the Board of Directors (the “Board”) of Blue Water Vaccines Inc. (the “Company”), as well as from her positions as chair of the of the Nominating and Corporate Governance Committee of the Board and as member each of the Compensation Committee and Audit Committee of the Board.

Appointed

Tim Ramdeen

Director

ONCO · Onconetix, Inc.

Effective: 2023-01-13
Filed: January 17, 2023, 6:59 PM ET

Effective as of January 13, 2023, the Board appointed Tim Ramdeen to replace Ms. Murphy and serve as a member of the Board, chair of the Nominating and Corporate Governance Committee of the Board and a member each of the Compensation Committee and Audit Committee of the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Kimberly Murphy resigned as Director at Onconetix, Inc..

Action: resigned
Role: Director

Exact text from the filing

Effective as of January 13, 2023, Kimberly Murphy resigned as a member of the Board of Directors (the “Board”) of Blue Water Vaccines Inc. (the “Company”), as well as from her positions as chair of the of the Nominating and Corporate Governance Committee of the Board and as member each of the Compensation Committee and Audit Committee of the Board.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Tim Ramdeen was appointed as Director at Onconetix, Inc..

Action: appointed
Role: Director

Exact text from the filing

Effective as of January 13, 2023, the Board appointed Tim Ramdeen to replace Ms. Murphy and serve as a member of the Board, chair of the Nominating and Corporate Governance Committee of the Board and a member each of the Compensation Committee and Audit Committee of the Board.

View on SEC.gov

Onconetix, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-23-002936

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.